Say Hy to the unique combination of IG + Hy

IG=Immune Globulin Infusion 10% (Human);

Hy=Recombinant Human Hyaluronidase.

Where IG meets Hy

HyQvia is an IG + Hy CIDP maintenance therapy for adults that is given subcutaneously. But it’s different from traditional IVIG and SCIG therapies because it’s made with a unique component: hyaluronidase, or Hy.

HyQvia is the only IG therapy that combines IG with Hy

Infusion icon depicting the unique combination of IG + Hy in HYQVIA.

IG in HyQvia is thought to reduce damage to the nerves and assist in defending the nerves from harm. HyQvia is similar to the IG in IVIG therapies.

Hy helps your body take in and disperse a larger amount of IG, which is why HyQvia can be infused monthly.*

*Every 2, 3, or 4 weeks.


How does Hy work?

Infusion needle inserted in fatty tissue directly beneath the skin, filled with hyaluronan.

Your body naturally contains hyaluronan

The fatty tissue directly beneath your skin is naturally filled with a substance called hyaluronan. 

Absence of Recombinant Human Hyaluronidase (Hy), limiting the amount of Ig that can be infused into the subQ tissue.

Hyaluronan limits the volume of IG you can infuse

Without the Hy in HyQvia, hyaluronan would limit the amount of IG that can be infused into the fatty tissue. 

Hy allowing a larger amount of Ig to reach the subQ tissue.

Hy makes room for a larger volume of IG

Hy allows for a larger amount of IG to reach the fatty tissue and be absorbed into the bloodstream.


Can relapses be prevented?

With CIDP, you may experience a range of symptoms, including muscle weakness in the arms and legs. Even after treatment with improvement, these symptoms can still occur—this is called a relapse.

HyQvia is a maintenance CIDP therapy that helps prevent relapses in adult patients

That means once you get your symptoms under control with stable doses of lVIG, your doctor may prescribe a maintenance therapy like HyQvia to help prevent relapse. In a 6-month clinical trial, relapse rates were different for people receiving HyQvia (14.0%) vs placebo (32.3%).

In a 6-month clinical trial*


or about 1.5 out of 10
people receiving HyQvia
experienced a relapse

In a 6-month clinical trial, 14% of people receiving HyQvia experienced a relapse.


In a 6-month clinical trial, 32.3% of people receiving placebo experienced a relapse.


or about 3 out of 10
people receiving placebo
experienced a relapse

*57 patients received HyQvia, and 65 patients received placebo.

      Those who did experience a relapse.

What are the common side effects of HyQvia?

Overall, the most common side effects are headache, fatigue, nausea, fever, itching, redness, abdominal pain, back pain, and pain in extremity.

Local side effects, meaning they occur around the infusion site, are common. This could be mild to moderate pain, redness, swelling, and itching.

These are not all the possible side effects for HyQvia. Talk to your healthcare professional about any side effects that bother you or that don't go away.

Please see additional Important Safety Information below, including Warning about Blood Clots.

CIDP=chronic inflammatory demyelinating polyneuropathy; IVIG=intravenous immune globulin; SCIG=subcutaneous immune globulin.

Ready to talk to your doctor?

Great. We’ve got just the thing for you. Our Doctor Discussion Guide can help you get organized and ready for your conversation with your doctor.

Doctor icon.